Clinical Trials

When the Stem Cell Network was first funded, its leadership considered that catalyzing a single clinical trial during its 14-year mandate would have been a success. Instead, the Network’s research investments have led to 12 clinical trials on various diseases, with even more in the development pipeline.

The Stem Cell Network was launched in 2001 to catalyze breakthroughs in regenerative medicine, and at that early stage it was believed that even one clinical trial in the Network’s 14 years would constitute a success. By the end of SCN’s funding term, however, its research investments led to 12 clinical trials—with more in the development pipeline—all with commercial and non-profit partners engaged and capable of carrying them to market approval.

Those clinical trials involve potential treatments for conditions ranging from leukemia and neuroblastoma, stroke, multiple sclerosis, pulmonary hypertension, septic shock and visual impairment, and took place in institutions across Canada and internationally. Many of these trials would not have been possible without SCN’s support and stewardship.


Furthermore, in order to streamline the process of future stem cell trials and treatments, SCN catalyzed a coordinated national cell-processing infrastructure, which will allow Canada to compete globally for new clinical trial business. SCN was also vital to the establishment of the CellCAN Regenerative Medicine and Cell Therapy Network, which was funded in 2014 to continue propelling research forward into clinical trials.

The Stem Cell Network’s investments in pre-clinical research and facilities have streamlined the clinical trials process and accelerated their development to ensure patients can access safe, effective regenerative medicine treatments more quickly.


Related Content

  • 2001-02 Annual Report, p. 13
  • 2008-09 Annual Report, p. 7
  • 2008-09 Annual Report, p. 9
  • 2011-12 Annual Report, p. 4
  • 2011-12 Annual Report, p. 7